These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34538541)

  • 61. Elexacaftor/Tezacaftor/Ivacaftor as a Bridge to Lung Retransplant in a Recipient With Cystic Fibrosis.
    FitzMaurice TS; Nazareth D; Iyer K; Walshaw M; Al-Aloul M
    Exp Clin Transplant; 2022 Apr; 20(4):433-435. PubMed ID: 35297329
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del.
    Taylor-Cousar JL; Munck A; McKone EF; van der Ent CK; Moeller A; Simard C; Wang LT; Ingenito EP; McKee C; Lu Y; Lekstrom-Himes J; Elborn JS
    N Engl J Med; 2017 Nov; 377(21):2013-2023. PubMed ID: 29099344
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Elexacaftor-Tezacaftor-Ivacaftor improves exercise capacity in adolescents with cystic fibrosis.
    Causer AJ; Shute JK; Cummings MH; Shepherd AI; Wallbanks SR; Pulsford RM; Bright V; Connett G; Saynor ZL
    Pediatr Pulmonol; 2022 Nov; 57(11):2652-2658. PubMed ID: 35851858
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review.
    Testa I; Indolfi G; Brugha R; Verkade HJ; Terlizzi V
    J Cyst Fibros; 2024 May; 23(3):554-560. PubMed ID: 38614868
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis.
    De Vuyst RC; Bennard E; Kam CW; McKinzie CJ; Esther CR
    Pediatr Pulmonol; 2023 May; 58(5):1592-1594. PubMed ID: 36718851
    [No Abstract]   [Full Text] [Related]  

  • 66. Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy.
    Heo S; Young DC; Safirstein J; Bourque B; Antell MH; Diloreto S; Rotolo SM
    J Cyst Fibros; 2022 Mar; 21(2):339-343. PubMed ID: 34742667
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of elexacaftor/tezacaftor/ivacaftor on liver fibrosis markers in adults with cystic fibrosis.
    Tewkesbury DH; Scott J; Barry PJ; Bright-Thomas RJ; Hanley KP; Athwal V; Jones AM
    J Cyst Fibros; 2024 Mar; 23(2):349-353. PubMed ID: 37735009
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor.
    Lowry S; Mogayzel PJ; Oshima K; Karnsakul W
    J Cyst Fibros; 2022 Mar; 21(2):e99-e101. PubMed ID: 34275759
    [No Abstract]   [Full Text] [Related]  

  • 69. Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation.
    Taylor-Cousar JL; Jain R
    J Cyst Fibros; 2021 May; 20(3):402-406. PubMed ID: 33762125
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lung clearance index (LCI
    Urquhart DS; Dowle H; Moffat K; Forster J; Cunningham S; Macleod KA
    Pediatr Pulmonol; 2024 May; 59(5):1449-1453. PubMed ID: 38415920
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis.
    Loske J; Völler M; Lukassen S; Stahl M; Thürmann L; Seegebarth A; Röhmel J; Wisniewski S; Messingschlager M; Lorenz S; Klages S; Eils R; Lehmann I; Mall MA; Graeber SY; Trump S
    Am J Respir Crit Care Med; 2024 Jun; 209(11):1338-1350. PubMed ID: 38259174
    [No Abstract]   [Full Text] [Related]  

  • 72. Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test.
    Mir-Ihara P; De Las Vecillas L; Heredia R; Fiandor A; González-Muñoz M; Zamarrón E; Prados C; Cabañas R
    J Investig Allergol Clin Immunol; 2024 Jun; 34(3):211-213. PubMed ID: 37966860
    [No Abstract]   [Full Text] [Related]  

  • 73. Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation.
    Gramegna A; Contarini M; Bindo F; Aliberti S; Blasi F
    Curr Opin Pharmacol; 2021 Apr; 57():81-88. PubMed ID: 33582393
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor.
    Duong JT; Pope CE; Hayden HS; Miller C; Salipante SJ; Rowe SM; Solomon GM; Nichols D; Hoffman LR; Narkewicz MR; Green N
    J Cyst Fibros; 2024 May; 23(3):490-498. PubMed ID: 38448281
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series.
    O'Connor KE; Goodwin DL; NeSmith A; Garcia B; Mingora C; Ladores SL; Rowe SM; Krick S; Solomon GM
    J Cyst Fibros; 2021 May; 20(3):399-401. PubMed ID: 33353860
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.
    Becq F; Mirval S; Carrez T; Lévêque M; Billet A; Coraux C; Sage E; Cantereau A
    Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34266939
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cystic fibrosis: Does it matter to avoid crushing Elexacaftor/Tezacaftor/Ivacaftor (ETI) tablets?
    Lebecque P; Thimmesch M; Meurrens J; Jeanmart P
    Pediatr Pulmonol; 2023 Dec; 58(12):3603-3604. PubMed ID: 37701935
    [No Abstract]   [Full Text] [Related]  

  • 78. Entering the era of highly effective modulator therapies.
    Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC
    Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis.
    Gabillard-Lefort C; Casey M; Glasgow AMA; Boland F; Kerr O; Marron E; Lyons AM; Gunaratnam C; McElvaney NG; Reeves EP
    Am J Respir Crit Care Med; 2022 Apr; 205(7):783-794. PubMed ID: 35021019
    [No Abstract]   [Full Text] [Related]  

  • 80. Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients.
    Wright BA; Ketchen NK; Rasmussen LN; Bartels AR; Singh SB
    Pediatr Pulmonol; 2022 Mar; 57(3):655-657. PubMed ID: 34859619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.